LITTLETON, Mass.–(BUSINESS WIRE)–Mevion Medical Systems, a leading provider of compact proton therapy systems for use in radiation therapy for cancer patients, announced today that the accelerator for the MEVION S250i Proton Therapy System® was delivered on July 28, 2022 to Tongji Hospital in Tongji. Faculty of Medicine, Huazhong University of Science and Technology, Wuhan, China. This milestone marks the start of installation of the system at Tongji Hospital’s Proton Therapy Center, the first of its kind in central China.
The system at Tongji Hospital includes Mevion’s leading HYPERSCAN® Pencil Beam Scanning (PBS) and Adaptive Aperture® pMLC technology. This powerful duo ensures faster and more precise targeted dose delivery to tumors, reducing damage to surrounding healthy tissue and organs at risk. The system also includes a diagnostic-quality CT imaging system and a surface tracking system for highly accurate patient positioning and intra-fraction motion management.
Founded in 1900, Tongji Hospital currently treats more than 6 million patients annually. It has developed into one of the largest and most powerful oncology medical education and research facilities in the world, and the recently opened Optics Valley Tongji Children’s Hospital is located on the same campus as the new Proton Therapy Center. In addition to the Mevion system, the new proton therapy center will also be equipped with a state-of-the-art whole-body PET/CT imaging system. Tongji Hospital also built a second proton vault, making it the first proton center in China to use One plus one multi-system installation approach. This approach gives cancer centers the flexibility to add a second system in the future to match patient growth and clinical expertise. With a phased deployment approach, financial burdens are significantly reduced at the start of a proton therapy clinical program, and the risk of technology obsolescence is greatly reduced.
“Mevion is excited to begin installing the system at the world-class Tongji Hospital, and we look forward to our continued partnership to provide much-needed access to proton therapy for patients in central China,” said Tina Yu, Ph.D. CEO and President of Mevion. “We are proud of our technology, which provides patients with advanced cancer treatment and enables hospitals to expand their proton therapy program at their own pace.”
*Mevion is actively seeking regulatory approval from the National Medical Products Administration (NMPA) in China.
About Mevion Medical Systems
Since 2004, Mevion Medical Systems has been a leading provider of compact proton therapy systems for cancer treatment. Committed to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to advance the science and application of proton therapy. Mevion’s flagship product, the MEVION S250i HYPERSCAN Pencil Beam Scanning Proton Therapy System, is the world’s smallest proton therapy system, eliminating the barriers of size, complexity and cost that exist with other proton therapy systems. Mevion is headquartered in Littleton, Massachusetts, with presence in Europe and Asia. For more information visit www.mevion.com.
Follow us on Twitter: @MevionMedical
Connect with us on LinkedIn: Mevion Medical Systems
Like us on Facebook: MevionMedical
About Tongji Hospital
Tongji Hospital was founded in Shanghai in 1900 by the German doctor Erich Paulun and moved to Wuhan in 1955. After more than 120 years of construction and development, it has now become a top-class innovative hospital in China. Tongji Hospital combines clinical services, teaching and scientific research with perfect disciplines, prestigious doctors, outstanding faculty, great clinical expertise, state-of-the-art diagnostic and therapeutic equipment, strong research facilities and efficient management. The Oncology Department of Tongji Hospital is one of the first oncology specialties established in China. After nearly 60 years of pioneering work and innovation, it has developed into one of the largest and most powerful oncology teaching and research institutions in central China.
“Alcohol scholar. Hardcore tv junkie. Wannabe bacon enthusiast. Twitter fanatic. Subtly charming travel guru. Pop culture specialist.”